PAVmed Inc. to Hold Business Update Conference Call on November 16th

PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly differentiated, multi-product medical device company, today announced that the Company will host a conference call on Thursday, November 16, 2017 at 4:30 p.m. Eastern time. During this call Lishan Aklog, M.D., the Company’s Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss third quarter 2017 financial results.

To access the conference call, U.S.-based listeners should dial [phone] and international listeners should dial [phone]. All listeners should provide the following passcode: 8082249. Individuals interested in listening to the live conference call via the internet may do so by visiting the Company’s website at www.pavmed.com.

Following the conclusion of the conference call, a replay will be available through November 22, 2017 and can be accessed by dialing [phone] from within the U.S. or [phone] from outside the U.S. All listeners should provide passcode: 8082249. The webcast will be available for a period of time on the Company’s website at www.pavmed.com.

About PAVmed Inc.

PAVmed Inc. (Nasdaq:PAVM, PAVMW) is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™) and pediatric ear infections (DisappEAR™).

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109005666/en/

InvestorsLHA Investor RelationsKim Sutton Golodetz, [e-mail]orMediaRooneyPartnersThomas Hynes, [e-mail]